Advertisement

Topics

Latest "Evrogen Joint Stock Company." News Stories

07:20 EST 21st November 2018 | BioPortfolio

Here are the most relevant search results for "Evrogen Joint Stock Company." found in our extensive news archives from over 250 global news sources.

More Information about Evrogen Joint Stock Company. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Evrogen Joint Stock Company. for you to read. Along with our medical data and news we also list Evrogen Joint Stock Company. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Evrogen Joint Stock Company. Companies for you to search.

Showing "Evrogen Joint Stock Company" News Articles 1–25 of 22,000+

Wednesday 21st November 2018

Biologics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryBiologics Inc Biologics, a subsidiary of McKesson Corp is a pharmacy service provider that offers oncology care and management services. The company offers consulting services, diseasespecific patient management programs, prior authorization support, oncology pharmacy services, strategic market solutions, clinical research services, patient access services, and reporting and analytics. Its ...


PellePharm to Present at Piper Jaffray Healthcare Conference

PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Piper Jaffray Healthcare Conference on Tuesday, November 27, at 12:30 p.m. EST in New York. A live webcast of...

Global and Asia Triethylene Glycol Hydrogenated Rosinate CAS: 68648533 Market Status and Future Forecast 20132023 [Report Updated: 20082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...


Eckert & Ziegler BEBIG: Convening Notice of the Extraordinary General Meeting of Shareholders

CONVENING NOTICE OF THEEXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Eckert & Ziegler BEBIGLimited Liability Company offering its securities to the publicIndustrial Zone C, 7180 SeneffeVAT BE 457.288.682Register of Legal Entities Hainaut - Division Charleroiwww.bebig.com (the "Company")  The shareholders of the Company are invited to attend the extraordinary general ...

Queen's University Belfast Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250

SummaryQueen's University Belfast Queen's University is an educational institution that offers education and research services. The institute provides undergraduate, professional development and postgraduate programs. Its postgraduate programs comprise postgraduate diploma in nursing, MSc advanced professional and clinical practice, master of philosophy, doctor of philosophy, a postgraduate certif...

Sage Therapeutics to Present at Piper Jaffray 30th Annual Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018 at 09:30 A.M. ET in New York, NY. ...

Multiple Myeloma Research Foundation Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 08112018] Prices from USD $250

SummaryMultiple Myeloma Research Foundation Inc MMRF is a nonprofit foundation that develops advanced multiple myeloma treatments. The foundation provides endtoend solutions for drug discovery and development targeting multiple myeloma. It provides clinical trails such as molecularly targeted therapies, noval therapies, and immune therapies. MMRF's offers educational programs for people suffering ...

Too late and too less for ASR hip joint used Indian victims!

The DePuy International Limited, a subsidiary of Johnson & Johnson, responsible for marketing and later withdrawing of Articular Surface Replacement (ASR) hip system, has just issued an advertisement in Newspaper stating

Miniature 2-Way Inert Solenoid Valve for Critical Fluid Control

Innovation in miniature continues to be the mission for THE LEE COMPANY proven by their ability to develop innovative miniature precision fluid control components. A good example of this is their new LFV Series 8000 2-way inert solenoid valve which is ideal for critical flow applications in clinical chemistry, flow cytometry and haematology machines. These 2-way chemically inert isolation style va...

Recro Pharma Inc REPH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryRecro Pharma Inc Recro Pharma is a specialty pharmaceutical company that focuses on developing novel products for commercialization in hospital and other acute care settings and provides contract development and manufacturing CDMO services. The company is developing IV/IM Meloxicam, a proprietary, rapidonset, longacting preferential COX2 inhibitor for the treatment of acute postoperative pa...

Italfarmaco SpA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryItalfarmaco SpA Italfarmaco, a subsidiary of Italfarmaco Holding SpA, is a pharmaceutical and chemical company which develops, manufactures, commercializes, and licences pharmaceutical drugs. The company's products portfolio includes antithrombotics, antihypertensive drugs, Vitamin and mineral supplements, peripheral vasodilators, antineoplastic drugs, antianemics, among others across the t...

GlycoMimetics Inc GLYC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryGlycoMimetics Inc GlycoMimetics is a clinicalstage biotechnology company that research, develops and commercializes small molecule drugs. The company's products comprise rivipansel GMI1070, under phase III clinical trial is an antiinflammatory compound to treat vasoocclusive crisis of sickle cell disease and blood cancers. It also provides GMI1271, galectin inhibitors, GMI 1359, GMI1051 an...

Direct Conversion AB Medical Equipment Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryDirect Conversion AB Direct Conversion formerly XCounter AB develops, manufactures and markets highperformance Xray imaging systems for medical, dental and industrial customers. It develops digital 3Dimaging systems for medical and industrial applications based on its proprietary Xray technologies. The company harnesses its patented XCT 3T technology to provide detectors incorporated into s...

Advanced Proteome Therapeutics Corp APC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryAdvanced Proteome Therapeutics Corporation APC is a biopharmaceutical company that focuses on the development of anticancer therapeutics that capitalizes on the properties of a natural human protein. It creates, develops and commercializes novel therapies. The company is advancing a sitespecific protein modification technology platform for the development of proprietary human protein pharma...

B.R.A.I.N. Biotechnology Research And Information Network AG: Manfred Bender set to join BRAIN AG's Management Board as Chief Financial Officer (CFO)

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Change of Personnel 21.11.2018 / 09:00 The issuer is solely responsible for the content of this announcement. Manfred Bender set to join BRAIN AG's Management Board as Chief Financial Officer (CFO) Appointed to the Management Board as of December 1, 2018, Bender to take over as CFO on January 1, 20...

Scientific Laboratory Supplies (SLS) identified in London Stock Exchange Group’s ‘1000 Companies to Inspire Europe’ report

UCB SA UCB Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryUCB SA UCB is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system CNS and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis ...

ViaCyte Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryViaCyte Inc ViaCyte, formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes. The company's pipeline products portfolio includes VC01, which is being developed as a therapy for T1D patients who have minimal to no insulinproducing beta cell function; and PECDirect, for type 1 diabetes patients that h...

Intellipharmaceutics International Inc IPCI Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryIntellipharmaceutics International Inc Intellipharmaceutics is a pharmaceutical company that researches, develops, manufactures, and commercializes novel and generic targeted oral solid dosage pharmaceuticals. The company develops its controlledrelease and targetedrelease oral solid dosage drugs based on its proprietary technology, Hypermatrix, a multidimensional controlledrelease drug deli...

EVOTEC AND IMMUNEERING TO COLLABORATE ON ARTIFICIAL INTELLIGENCE ('AI') DRIVEN LIGAND IDENTIFICATION FOR RARE HEREDITARY METABOLIC DISEASES

DGAP-News: Evotec AG / Key word(s): Miscellaneous 21.11.2018 / 07:30 The issuer is solely responsible for the content of this announcement. COMBINATION OF CUTTING-EDGE IPSC AND AI TECHNOLOGIES CREATES OPPORTUNITY TO DISCOVER NOVEL METABOLIC LIGANDS TO ACCELERATE DRUG DISCOVERY IN RARE METABOLIC DISEASES   Hamburg, Germany, and Cambridge, USA, 21 November 2018: Evotec AG (Frankf...

Bio Farma : Sharing experience in acquiring WHO Pre-qualification to OIC Member Countries

M. Rahman Roestan, President Director of Bio Farma, has been invited to speak on Bio Farma’s experience in acquiring WHO pre-qualification for Vaccines, at The First Meeting of Heads of National Medicines Regulatory Authorities (NMRAs) held by National Agency of Drug and Food Monitoring (BPOM) of Indonesia. Rahman said,“currently Bio Farma has...

Huadong Medicine Closes $220 Million Acquisition of the UK's Sinclair Pharma

Huadong Medicine closed its $222 million acquisition of Sinclair Pharma, a global aesthetics company headquartered in London. Huadong is also a maker of aesthetic products and plans to bring Sinclair's offerings to China while it builds a larger presence for both companies' offerings in the US. Sinclair, on the other hand, says it will use Huadong's backing to increase its own portfolio of longer-...

CASI Pharma to Build Manufacturing Plant in Wuxi, China

CASI Pharma, a US-China company, announced plans to build a global cGMP manufacturing facility in Wuxi, China. In January of this year, CASI acquired global rights to a portfolio of 29 generic drugs from Sandoz. Most of the products are approved in the US, but CASI has plans to make and market them in China. Headquartered in Maryland, CASI has an R&D facility in Beijing. More details.... Stock...

Gilead Approved in China to Market Vemlidy for Hepatitis B

Gilead Sciences announced approval to market Vemlidy® (tenofovir alafenamide), an oral treatment for hepatitis B, in China. In clinical trials, Vemlidy showed non-inferiority to another Gilead drug, Viread®. Both drugs are nucleoside reverse transcriptase inhibitors based on tenofovir. But Gilead said Vemlidy delivers tenofovir to hepatocytes more efficiently than Viread, allowing the same...

Arsanis Inc ASNS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryArsanis Inc Arsanis is a clinicalstage biopharmaceutical company that focuses on the development of monoclonal antibody immunotherapies for the treatment of critical infectious diseases. The company's pipeline product portfolio includes ASN100, for staphylococcus aureus; ASN500, targets respiratory syncytial virus RSV; ASN300, for klebsiella pneumonia; and ASN200, for escherichia coli. Arsa...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks